Hot flashes happened less often and were less severe in women who took elinzanetant compared to those who took a placebo. The ...

For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive ...

Hydrocortisone oral solution (Khindivi) was approved as a replacement therapy for pediatric patients ages 5 years and up with ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

A low-fat vegan diet, regardless of food processing level, can reduce hot flashes by 92% and promote weight loss, a new study ...

meaning they were experiencing hot flashes 14 or more times a week and the hot flashes were bothersome or severe on four or more days or nights per week. Investigators found that on average about ...

Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, ...

Hot flashes are one of the most common symptoms that are seen in menopausal women. Here's all you need to know about it.

When the FDA approved fezolinetant for treating moderate to severe hot flashes in menopausal women, the news made headlines.